David Hong

David Hong at MD Anderson is one of the most prolific phase I oncology trial investigators, having conducted early clinical development of many approved agents. He led early phase trials of larotrectinib demonstrating tumor-agnostic activity in NTRK fusion-positive cancers — a landmark result demonstrating unprecedented histology-independent response rates that led to the first tumor-agnostic FDA approval based on molecular alteration. He has also contributed to NCI-MATCH and other basket trial designs.